{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:23Z","timestamp":1793338823712,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["BLISS-LN"],"award-info":[{"award-number":["BLISS-LN"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK Study 114054"],"award-info":[{"award-number":["GSK Study 114054"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT01639339"],"award-info":[{"award-number":["NCT01639339"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001463","name":"American Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kint.2026.03.030","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:10:24Z","timestamp":1779376224000},"page":"451-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis"],"prefix":"10.1016","volume":"110","author":[{"given":"Richard","family":"Furie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.03.030_bib1","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.03.030_bib2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.03.030_bib5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2026.03.030_bib28","unstructured":"Efficacy and Safety of Belimumab in Patients with Active Lupus Nephritis (BLISS-LN). ClinicalTrials.gov Identifier: NCT01639339. Updated March 19, 2021. Accessed February 26, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01639339"},{"key":"10.1016\/j.kint.2026.03.030_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.030_bib7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.030_bib29","unstructured":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN\/RPS 2003 Class III or IV Lupus Nephritis (REGENCY). ClinicalTrials.gov Identifier: NCT04221477. Updated May 11, 2026. Accessed June 3, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04221477"},{"key":"10.1016\/j.kint.2026.03.030_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ero.2025.07.006","article-title":"Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations","volume":"1","author":"Kostopoulou","year":"2025","journal-title":"EULAR Rheumatol Open"},{"key":"10.1016\/j.kint.2026.03.030_bib9","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.03.030_bib10","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.03.030_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.030_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.03.030_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.03.030_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4078\/jrd.22.0006","article-title":"Predictive factors for renal response in lupus nephritis: a single-center prospective cohort study","volume":"29","author":"Park","year":"2022","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.kint.2026.03.030_bib15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ekir.2020.04.005","article-title":"Low-grade proteinuria does not exclude significant kidney injury in lupus nephritis","volume":"5","author":"De Rosa","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.030_bib30","unstructured":"Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN (OBSErve-LN). ClinicalTrials.gov Identifier: NCT06527872. Updated March 27, 2026. Accessed June 3 2026. https:\/\/clinicaltrials.gov\/study\/NCT06527872"},{"key":"10.1016\/j.kint.2026.03.030_bib16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.030_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN): results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto","year":"2021","journal-title":"J Autoimmunity"},{"key":"10.1016\/j.kint.2026.03.030_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kead707","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study","volume":"64","author":"Lin","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2026.03.030_bib19","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/rheumatology\/keae495","article-title":"Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry","volume":"64","author":"Sakai","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2026.03.030_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-024-03389-4","article-title":"Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2026.03.030_bib21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.030_bib22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/09612033221131183","article-title":"Safety of belimumab in adult patients with systemic lupus erythematosus: results of a large integrated analysis of controlled clinical trial data","volume":"31","author":"Wallace","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2026.03.030_bib23","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.kint.2026.03.030_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022328","article-title":"Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis","volume":"99","author":"Jiang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2026.03.030_bib25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.kint.2026.03.030_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102827","article-title":"High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients","volume":"129","author":"Fabris","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.kint.2026.03.030_bib27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/09612033221151012","article-title":"Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with belimumab","volume":"32","author":"Schiavoni","year":"2023","journal-title":"Lupus"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:11:57Z","timestamp":1786482717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826003972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0085253826003972"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}